Arvinas (NASDAQ:ARVN) Shares Gap Down After Earnings Miss

Arvinas, Inc. (NASDAQ:ARVN)’s stock price gapped down before the market opened on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $12.30, but opened at $11.33. Arvinas shares last traded at $11.8650, with a volume of 296,398 shares.

The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company had revenue of $9.50 million for the quarter, compared to analysts’ expectations of $37.26 million. During the same period in the previous year, the business posted ($0.63) EPS. The business’s quarterly revenue was down 84.0% on a year-over-year basis.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Company says it has a cash runway into the second half of 2028 and outlined multiple 2026 clinical-data milestones (ARV-102, ARV-806, ARV-393) that could drive value if readouts are positive. This financial runway reduces near-term financing risk and supports ongoing development. Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of
• Positive Sentiment: Program progress: ARV-102 (LRRK2) accepted for an oral presentation at AP/PD; ARV-806 (KRAS G12D) and ARV-393 (BCL6) clinical data on track; ARV-027 Phase 1 in healthy volunteers started; ARV-6723 Phase 1 planned mid-2026. Management change (Randy Teel, Ph.D., named CEO) also highlighted. These operational updates support a constructive view on pipeline execution. Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Management is increasing investor access (TD Cowen fireside chat and other conferences in early March), which could improve visibility and catalyze re-assessment of the pipeline by sell-side and institutional investors. Arvinas to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Intraday volume was noticeably higher than average and the stock is trading above its 50-day moving average, suggesting short-term investor interest and technical buying even amid mixed fundamentals. (Market trading data)
• Negative Sentiment: Q4 2025 results materially missed expectations: GAAP EPS of -$1.10 vs. consensus -$0.55 and revenue $9.5M vs. $37.3M expected (revenue down ~84% YoY). The magnitude of the revenue shortfall and larger-than-expected loss raise near-term execution and commercial concerns. Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Analyst outlook remains negative on near-term profitability (consensus and analyst commentary point to continuing losses and negative EPS for the year), which limits upside until clinical readouts materially de-risk programs. 4ARVN : Arvinas’s Earnings Outlook

Analyst Ratings Changes

ARVN has been the topic of a number of recent research reports. Wedbush restated a “neutral” rating and issued a $11.00 target price on shares of Arvinas in a report on Tuesday. Barclays boosted their price objective on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wells Fargo & Company decreased their price objective on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Wall Street Zen upgraded Arvinas from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, BTIG Research lifted their price target on Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Ten investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $13.24.

Insiders Place Their Bets

In other news, insider Noah Berkowitz sold 5,685 shares of Arvinas stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $67,594.65. Following the sale, the insider owned 163,938 shares in the company, valued at $1,949,222.82. This trade represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Randy Teel sold 4,403 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $52,351.67. Following the completion of the transaction, the chief executive officer owned 154,482 shares of the company’s stock, valued at $1,836,790.98. This trade represents a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,238 shares of company stock worth $193,070 over the last quarter. 4.73% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arvinas

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC lifted its stake in shares of Arvinas by 7.2% in the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock worth $176,000 after acquiring an additional 993 shares in the last quarter. Intech Investment Management LLC increased its holdings in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after purchasing an additional 1,125 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after acquiring an additional 1,381 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after acquiring an additional 2,122 shares in the last quarter. Finally, Oxford Asset Management LLP grew its holdings in Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after acquiring an additional 2,242 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Trading Up 0.6%

The company has a market cap of $794.40 million, a P/E ratio of -15.27 and a beta of 1.88. The company’s 50-day moving average price is $12.37 and its two-hundred day moving average price is $10.51.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.